AstraZeneca Plc (AZN: Quote,AZN.L) said Thursday that the US District Court for the District of New Jersey has found the formulation patent protecting SEROQUEL XR (quetiapine fumarate) extended release tablets to be valid.
According to the company, the court has ruled that Anchen Pharmaceuticals Inc., Osmotica Pharmaceutical Corp., Torrent Pharmaceuticals Limited, Torrent Pharma Inc., Mylan Pharmaceuticals Inc., and Mylan Inc. (MYL) have infringed the SEROQUEL XR formulation patent. The SEROQUEL XR formulation patent expires in 2017.
The decision follows a ruling made in the UK on March 22, 2012, which found the formulation patent protecting SEROQUEL XR to be invalid. In the Netherlands, however, on March 7, 2012, the District Court in The Hague found the formulation patent protecting SEROQUEL XR to be valid.
AstraZeneca said it is pleased with the US District Court's decision, which the company believes underlines the strength of its patents.
Seroquel generated $5.83 billion in global sales last year, with $1.4 billion coming from Seroquel XR.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org